Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, University of Medical Sciences, Tehran, Iran.
Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Mol Biol Rep. 2022 Aug;49(8):7849-7862. doi: 10.1007/s11033-022-07615-7. Epub 2022 Jun 22.
Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML.
在此，我们旨在研究前列腺素内过氧化物合酶 2（PTGS2）和血管内皮生长因子-C（VEGF-C）的表达以及 AML 患者中 PTGS2 的甲基化。通过定量逆转录 PCR 方法评估新诊断的 AML 患者和健康对照者中 VEGF-C 和 PTGS2 的表达分析。此外，通过甲基化敏感高分辨率熔解曲线分析（MS-HRM）评估 PTGS2 甲基化状态。患者中 34%为女性，患者的平均年龄为 43.41±17.60 岁，主要患有 AML M4（48.21%）型。虽然患者与对照组之间的甲基化水平无显著差异，但正常对照组中均未发现 PTGS2 启动子甲基化。AML 病例中 PTGS2 和 VEGF-C 水平升高，并与白细胞、血小板和血红蛋白水平相关。过表达 VEGF-C 和 PTGS2 的患者的生存率比其他患者差。可以得出结论，PTGS2 特别是 VEGF-C 的表达而不是 PTGS2 的甲基化可以被认为是 AML 的诊断生物标志物。
